Skip to main content

FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults

FDA staff said Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.